keyword
https://read.qxmd.com/read/38492205/liquid-biopsy-for-breast-cancer-and-other-solid-tumors-a-review-of-recent-advances
#21
JOURNAL ARTICLE
Hirofumi Ohmura, Fumiyasu Hanamura, Yuta Okumura, Yuki Ando, Takaaki Masuda, Koshi Mimori, Koichi Akashi, Eishi Baba
Liquid biopsy using circulating tumor DNA (ctDNA) has been reported to be less invasive and effective for comprehensive genetic analysis of heterogeneous solid tumors, including decision-making for therapeutic strategies, predicting recurrence, and detecting genetic factors related to treatment resistance in various types of cancers. Breast cancer, colorectal cancer, and lung cancer are among the most prevalent malignancies worldwide, and clinical studies of liquid biopsy for these cancers are ongoing. Liquid biopsy has been used as a companion diagnostic tool in clinical settings, and research findings have accumulated, especially in cases of colorectal cancer after curative resection and non-small cell lung cancer (NSCLC) after curative chemoradiotherapy, in which ctDNA detection helps predict eligibility for adjuvant chemotherapy...
March 16, 2024: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://read.qxmd.com/read/38491203/a-novel-approach-to-computing-preference-estimates-for-different-treatment-pathways-an-application-in-oncology
#22
JOURNAL ARTICLE
Kathleen Beusterien, Oliver Will, Emuella Flood, Susan McCutcheon, deMauri S Mackie, Stella Mokiou
BACKGROUND: Patients with cancer may progress through multiple treatments with differing adverse effect profiles. Moreover, pathways may be fixed or flexible in allowing for escalation or de-escalation of treatment depending on interim outcomes. We sought to develop a methodology capable of estimating preferences for the entirety of a pathway involving a sequence of different treatments. METHODS: Patients with early breast cancer completed an online discrete choice experiment to assess preferences for eight key early breast cancer attributes...
March 15, 2024: Patient
https://read.qxmd.com/read/38491128/evaluating-persistent-t1-weighted-lesions-without-concurrent-abnormal-enhancement-on-breast-mri-in-neoadjuvant-chemotherapy-patients-implications-for-complete-pathological-response
#23
JOURNAL ARTICLE
Shahine Goulam-Houssein, Xiang Y Ye, Rachel Fleming, Frederick Au, Supriya Kulkarni, Sandeep Ghai, Yoav Amitai, Michael Reedijk, Vivianne Freitas
OBJECTIVE: This study aims to determine whether persistent T1-weighted lesions signify a complete pathological response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy and surgery, and to evaluate their correlation with imaging responses on MRI. MATERIALS AND METHODS: A retrospective review was conducted on data from breast cancer patients treated between January 2011 and December 2018. Patients who underwent breast MRI and pre- and post-neoadjuvant chemotherapy followed by surgery were included...
March 16, 2024: European Radiology
https://read.qxmd.com/read/38490656/adjuvant-chemotherapy-and-survival-outcomes-in-older-women-with-hr-her2-breast-cancer-a-propensity-score-matched-retrospective-cohort-study-using-the-seer-database
#24
JOURNAL ARTICLE
Xindi Ma, Shang Wu, Xiangmei Zhang, Nannan Chen, Chenhui Yang, Chao Yang, Miao Cao, Kaiye Du, Yunjiang Liu
OBJECTIVES: This study aimed to investigate the impact of adjuvant chemotherapy (ACT) on survival outcomes in older women with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer (BC). DESIGN: A retrospective cohort study using data from the Surveillance, Epidemiology, and End Results database, which contains publicly available information from US cancer registries. SETTING AND PARTICIPANTS: The study included 45 762 older patients with BC aged over 65 years diagnosed between 2010 and 2015...
March 15, 2024: BMJ Open
https://read.qxmd.com/read/38489717/construction-and-validation-of-nomogram-for-the-cancer-specific-mortality-for-her2-positive-breast-cancer-patients
#25
JOURNAL ARTICLE
Nan Wu
The cancer-specific mortality (CSM) of patients with human epidermal growth factor receptor 2 positive (HER2+) breast cancer remains dismal and varies widely from person to person. Therefore, we aim to construct a nomogram to predict CSM in HER2+ breast cancer using data from the surveillance, epidemiology, and end results (SEER) database. The clinicopathological data of patients diagnosed with HER2+ breast cancer from 2000 to 2019 were selected from the SEER database. Independent prognostic factors for CSM of patients were identified by competing risk model...
March 15, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38489305/cost-effectiveness-of-one-year-adjuvant-trastuzumab-therapy-in-treatment-for-early-stage-breast-cancer-patients-with-her2-in-vietnam
#26
JOURNAL ARTICLE
Anh Quynh Nguyen, Oanh Thi Mai Tran, Phuong Khanh Nguyen, Ha Thu Nguyen
BACKGROUND: In Vietnam, trastuzumab is included in social health insurance's benefits package with a reimbursement rate of 60%, but policymakers have been concerned about its cost-effectiveness. The research aims to evaluate the cost-effectiveness of one-year adjuvant trastuzumab therapy for early-stage breast cancer patients with human epidermal growth receptor 2 (HER2+) from a societal perspective. METHOD: A Markov model was developed and validated to estimate the lifetime cost and effectiveness (using life year and quality-adjusted life year) of one-year adjuvant trastuzumab therapy compared to chemotherapy (using paclitaxel) alone...
2024: PloS One
https://read.qxmd.com/read/38489166/use-of-axillary-ultrasound-to-guide-breast-cancer-management-in-the-genomic-assay-era
#27
JOURNAL ARTICLE
Geok Hoon Lim, John Carson Allen, Yien Sien Lee, Sze Yiun Teo, Li Ching Lau, Thida Win, Lester Chee Hao Leong
INTRODUCTION: Chemotherapy is conventionally offered to non-stage IV breast cancer patients with metastatic nodes. However, the RxPONDER trial showed that chemotherapy can be omitted in selected patients with 1-3 metastatic nodes if the 21-gene assay recurrence score is ≤25. We aimed to investigate if axillary ultrasound can identify this group of patients with limited nodal burden so that they can undergo upfront surgery followed by gene assay testing, to potentially avoid chemotherapy...
2024: Breast Disease
https://read.qxmd.com/read/38489021/a-systematic-review-of-health-related-quality-of-life-in-women-with-her2-positive-metastatic-breast-cancer-treated-with-trastuzumab
#28
Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Lisa Aniek de Jong, Didik Setiawan, Maarten Jacobus Postma
BACKGROUND: Many trials of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer treatment with trastuzumab have provided evidence of improved clinical outcomes. This systematic review examined how a regimen that includes trastuzumab affects patients' health-related quality of life (HRQoL) during and after treatment. METHODS: A systematic search for articles published up to February 2023 without restrictions of language or publication year was performed using the Pubmed, Embase, and Scopus databases...
March 15, 2024: PharmacoEconomics Open
https://read.qxmd.com/read/38487087/exploring-the-vast-potentials-and-probable-limitations-of-novel-and-nanostructured-implantable-drug-delivery-systems-for-cancer-treatment
#29
REVIEW
Maryam Ebrahimnia, Sonia Alavi, Hamed Vaezi, Mahdieh Karamat Iradmousa, Azadeh Haeri
Conventional cancer chemotherapy regimens, albeit successful to some extent, suffer from some significant drawbacks, such as high-dose requirements, limited bioavailability, low therapeutic indices, emergence of multiple drug resistance, off-target distribution, and adverse effects. The main goal of developing implantable drug delivery systems (IDDS) is to address these challenges and maintain anti-cancer drugs directly at the intended sites of therapeutic action while minimizing inevitable side effects. IDDS possess numerous advantages over conventional drug delivery, including controlled drug release patterns, one-time drug administration, as well as loading and stabilizing poorly water-soluble chemotherapy drugs...
2024: EXCLI Journal
https://read.qxmd.com/read/38486987/phase-separation-of-nur77-mediates-xs561-induced-apoptosis-by-promoting-the-formation-of-nur77-bcl-2-condensates
#30
JOURNAL ARTICLE
Xiaohui Chen, Meichun Gao, Yongzhen Xia, Xin Wang, Jingbo Qin, Hongying He, Weirong Liu, Xiaowei Zhang, Shuangzhou Peng, Zhiping Zeng, Ying Su, Xiaokun Zhang
The orphan nuclear receptor Nur77 is a critical regulator of the survival and death of tumor cells. The pro-death effect of Nur77 can be regulated by its interaction with Bcl-2, resulting in conversion of Bcl-2 from a survival to killer. As Bcl-2 is overexpressed in various cancers preventing them from apoptosis and promoting their resistance to chemotherapy, targeting the apoptotic pathway of Nur77/Bcl-2 may lead to new cancer therapeutics. Here, we report our identification of XS561 as a novel Nur77 ligand that induces apoptosis of tumor cells by activating the Nur77/Bcl-2 pathway...
March 2024: Acta Pharmaceutica Sinica. B
https://read.qxmd.com/read/38485557/stromal-type-i-collagen-in-breast-cancer-correlation-to-prognostic-biomarkers-and-prediction-of-chemotherapy-response
#31
JOURNAL ARTICLE
Malin Jansson, Jessica Lindberg, Gunilla Rask, Johan Svensson, Ola Billing, Anoosheh Nazemroaya, Anette Berglund, Fredrik Wärnberg, Malin Sund
INTRODUCTION: Fibrillar collagens accumulate in the breast cancer stroma and appear as poorly defined spiculated masses in mammography imaging. The prognostic value of tissue type I collagen remains elusive in treatment-naïve and chemotherapy-treated breast cancer patients. Here, type I collagen mRNA and protein expression were analysed in 2 large independent breast cancer cohorts. Levels were related to clinicopathological parameters, prognostic biomarkers, and outcome. METHOD: COL1A1 mRNA expression was analysed in 2509 patients with breast cancer obtained from the cBioPortal database...
February 21, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38484493/evaluation-of-traditional-targeted-axillary-dissection-eligibility-criteria-for-node-positive-breast-cancer-after-neoadjuvant-chemotherapy-in-a-prospective-multicenter-registry
#32
JOURNAL ARTICLE
Catherine Loveland-Jones, John Gaughan, Abigail Caudle, Brittany Murphy, Laila Samiian, Stephanie Byrum, Kristen Brill, Pauline Germaine, Xinmin Zhang, Kay Yoon-Flannery, Teralyn Carter, Adrian Lopez, Ryan Gruner, Michele Fantazzio, Henry Kuerer
INTRODUCTION: Targeted axillary dissection (TAD) is performed after neoadjuvant systemic therapy (NST) to decrease the rate of non-therapeutic axillary dissection (ALND) for patients with node-positive breast cancer. In order to ensure the oncologic safety of TAD, eligibility criteria resulting in a low false negative rate (FNR) have been proposed. The purpose of this study was to evaluate the utility of the traditional criteria. METHODS: Data was collected from a prospective multicenter registry...
March 3, 2024: European Journal of Surgical Oncology
https://read.qxmd.com/read/38483821/carbon-coated-iron-oxide-nanoparticles-promote-reductive-stress-mediated-cytotoxic-autophagy-in-drug-induced-senescent-breast-cancer-cells
#33
JOURNAL ARTICLE
Anna Lewińska, Adrian Radoń, Kacper Gil, Dominika Błoniarz, Agnieszka Ciuraszkiewicz, Jerzy Kubacki, Mariola Kądziołka-Gaweł, Dariusz Łukowiec, Piotr Gębara, Agnieszka Krogul-Sobczak, Piotr Piotrowski, Oktawia Fijałkowska, Sylwia Wybraniec, Tomasz Szmatoła, Aleksandra Kolano-Burian, Maciej Wnuk
The surface modification of magnetite nanoparticles (Fe3 O4 NPs) is a promising approach to obtaining biocompatible and multifunctional nanoplatforms with numerous applications in biomedicine, for example, to fight cancer. However, little is known about the effects of Fe3 O4 NP-associated reductive stress against cancer cells, especially against chemotherapy-induced drug-resistant senescent cancer cells. In the present study, Fe3 O4 NPs in situ coated by dextran (Fe3 O4 @Dex) and glucosamine-based amorphous carbon coating (Fe3 O4 @aC) with potent reductive activity were characterized and tested against drug-induced senescent breast cancer cells (Hs 578T, BT-20, MDA-MB-468, and MDA-MB-175-VII cells)...
March 14, 2024: ACS Applied Materials & Interfaces
https://read.qxmd.com/read/38482672/changes-in-breast-cancer-grade-from-biopsy-to-excision-following-surgery-or-primary-chemotherapy
#34
JOURNAL ARTICLE
Ádám Ferenczi, Gábor Cserni
OBJECTIVE: To compare histological grade (G) of breast cancer and its components (scores for tubule formation - T, nuclear pleomorphism - P and mitotic counts - M) in core needle biopsies (CNBs) and surgical excision specimens (EXC) in patients treated with primary surgery (CHIR) or primary chemotherapy (PST). METHODS: Grade of matched pairs of carcinomas in CNB and EXC was assessed according to the Nottingham grading system. RESULTS: PST cases tended to have higher pretreatment G...
February 2024: Pathologica
https://read.qxmd.com/read/38482560/synergistic-effects-of-epoxyazadiradione-ead-and-paclitaxel-against-triple-negative-breast-cancer-cells
#35
JOURNAL ARTICLE
Kunnathully Sudhan Sijisha, Rajitha Anusha, Sulochana Priya
BACKGROUND: Triple-negative breast cancer (TNBC) is the most aggressive and chemo-resistant form of breast cancer subtype, and chemotherapy is a vital treatment option for that. Paclitaxel is an effective chemo drug for TNBC. However, in clinical settings, paclitaxel has adverse side effects. The synergistic combination is the most promising method for overcoming undesirable toxicity and achieving a beneficial therapeutic outcome. Previous reports, including our study, showed certain anticancer potential of epoxyazadiradione (EAD), the neem limonoid, in different types of cancer cells, including TNBC...
March 14, 2024: Fundamental & Clinical Pharmacology
https://read.qxmd.com/read/38482410/development-of-a-multiparametric-model-for-predicting-the-response-to-neoadjuvant-chemotherapy-in-breast-cancer
#36
JOURNAL ARTICLE
Fusheng Qian, Yajing Mao, Jie Dong, Feiyue Xie, Xin Fang, Qian Zhang, Panpan Xia, Xinghua Han, Nannan Lu
BACKGROUND: Choosing the appropriate treatment early and predicting the efficacy of neoadjuvant chemotherapy (NAC) for locally advanced breast cancer patients are of particular importance for clinicians. Developing and validating a multiparametric model for predicting NAC would be very meaningful for clinical practice. METHODS: This study included 91 patients with locally advanced breast cancer treated from 2016 to 2020. The correlation between multiparametric characteristics and the efficacy of NAC was examined...
February 29, 2024: Translational Cancer Research
https://read.qxmd.com/read/38482077/comparative-study-of-the-effects-of-duloxetine-and-venlafaxine-on-acute-symptomatic-taxane-induced-neuropathy-in-breast-cancer-patients-a-randomized-clinical-trial
#37
JOURNAL ARTICLE
Hanieh Radkhah, Mohsen Esfandbod, Mohammad Amin Khadembashiri, Mohammad Eslami, Farnaz Etesam, Farhad Shahi, Parnian Shobeir, Melika Rafiemehr
INTRODUCTION: Chemotherapeutic agents have the potential to induce neurotoxicity, resulting in a range of symptoms, including mild paresthesia, neuropathic pain, pronounced ataxia, and significant impairment. Taxane-induced neuropathy (TIN) is a prevalent adverse effect and a significant constraint of Taxane-based chemotherapy protocols in treating breast cancer. In this current study, we aim to compare the effects of Venlafaxine and Duloxetine in taxane-induced Neuropathy as well as the quality of life, Depression, and Anxiety in Breast cancer Patients...
2024: Journal of Community Hospital Internal Medicine Perspectives
https://read.qxmd.com/read/38481595/metaplastic-breast-cancer-with-squamous-differentiation-beyond-the-recognized-statistics
#38
Rania Zaki Fallatah, Dhuha N Boumarah, Ghadeer Hajjaj, Abdullah Ahmed Alkhars, Mohammed AlDuhileb
BACKGROUND: Metaplastic breast cancer is a clinically rare subtype of breast carcinomas, accounting for less than 1% of all breast neoplasms, and was not officially recognized till the end of the 20th century as an independent pathological diagnosis. OBJECTIVE: In this paper, we report a case of metaplastic breast cancer with squamous differentiation in a 51-year-old female, with a succinct review of the literature. CASE REPORT: The patient presented to our outpatient department with a complaint of left breast mass for 2 months duration with a diagnostic workup found to be grade three metaplastic carcinoma with squamous differentiation...
2024: Medical Archives
https://read.qxmd.com/read/38481526/feasibility-and-tolerability-of-eribulin-based-chemotherapy-versus-other-chemotherapy-regimens-for-patients-with-metastatic-triple-negative-breast-cancer-a-single-centre-retrospective-study
#39
JOURNAL ARTICLE
Weiwei Huang, Chenxi Wang, Lili Wang, Yangkun Shen, Qi Chen, Zhijian Huang, Jian Liu, Xiaoyan Lin, Fan Wu, Xinhua Chen, Nani Li, Yi Hong, Mulan Chen, Jieyu Li, Chuanzhong Huang
Background: Patients with Triple-negative breast cancer (TNBC) face a poor prognosis and limited therapeutic options. Current data on eribulin usage to treat TNBC is scarce. Therefore, we sought to compare the feasibility and tolerability of eribulin-based regimens with other chemotherapy regimens in patients with TNBC. Method: This retrospective study was conducted at Fujian Medical University Cancer Hospital and included 159 patients with TNBC enrolled between October 2011 and January 2023. Patients underwent treatment with eribulin-based and other chemotherapy regimens...
2024: Frontiers in Cell and Developmental Biology
https://read.qxmd.com/read/38481446/concurrent-neoadjuvant-endocrine-therapy-with-chemotherapy-in-hr-her2-breast-cancer-a-systematic-review-and-meta-analysis
#40
Ping Wu, Wenjie Lv
UNLABELLED: The role of simultaneous neoadjuvant endocrine therapy in chemotherapy in HR+HER2- breast cancer continues to be controversial. This systematic review and meta-analysis was conducted to further evaluate the effectiveness and safety of this strategy for HR+HER2- breast cancer patients. Trials in which HR+HER2- breast cancer patients were randomly assigned to either single or simultaneous endocrine-assisted neoadjuvant chemotherapy were eligible for inclusion. The prime endpoint was the pathological complete response (pCR) rate...
2024: Frontiers in Endocrinology
keyword
keyword
40931
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.